CDK4/6 blockade provides an alternative approach for treatment of mismatch-repair deficient tumors
Sign Up to like & getrecommendations! Published in 2022 at "Oncoimmunology"
DOI: 10.1080/2162402x.2022.2094583
Abstract: ABSTRACT Mismatch repair-deficient (dMMR) tumors show a good response toward immune checkpoint inhibitors (ICI), but developing resistance impairs patients’ outcomes. Here, we compared the therapeutic potential of an α-PD-L1 antibody with the CDK4/6 inhibitor abemaciclib… read more here.
Keywords: mismatch repair; wks wks; repair deficient; treatment ... See more keywords